CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors

Mingyao Huang, Youchen Cui, Xiaoqian Wang, Yang Weng, Huiyan Huang, Weiwei Su, Shan Zhao, Yan Li · 2026

Read CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors by Mingyao Huang, Youchen Cui, Xiaoqian Wang, Yang Weng, Huiyan Huang, Weiwei Su, Shan Zhao, Yan Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13390371.txt.

Description

Mingyao Huang's team reviews CD155, the polio virus sensor, and its sensors as immune checkpoint targets in glioma, a fast-moving brain cancer with a strongly damping immune setting and poor treatment response. CD155 is often run high in glioma and tunes defences through blocking sensors TIGIT and CD96 plus the switching-on sensor CD226.

Those links blunt killer T cell and natural killer cell activity while fostering control forms, helping tumours escape destruction. Immune drugs, dual-target immune drugs, and CAR-built immune cells targeting the CD155 axis are in testing. The review weighs their promise against the hurdles of breaking glioma immune damping.

Catalog record

CREATORMingyao Huang, Youchen Cui, Xiaoqian Wang, Yang Weng, Huiyan Huang, Weiwei Su, Shan Zhao, Yan Li
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13390371

Browse the full library · About the Tower of Babel